Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: Tracking evolution and identifying mutations by whole-genome sequencing

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 349-354

  Chen, Chih Jung ^a,b   Lin, Mei Hui ^b,c   Shu, Jwu Ching ^b   Lu, Jang Jih ^b,d  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Genetic evolution; ST59; Vancomycin intermediate Staphylococcus aureus

Indexed keywords

AGRC PROTEIN; BACTERIAL PROTEIN; FUSA PROTEIN; FUSIDIC ACID; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; EVOLUTIONARY ADAPTATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KNEE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONSENSE MUTATION; PHENOTYPE; POINT MUTATION; SCREENING TEST; SEPSIS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

GENETIC EVOLUTION; ST59; VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS;

AGED; ANTI-BACTERIAL AGENTS; EVOLUTION, MOLECULAR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; POLYMORPHISM, GENETIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84892457481     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt395     Document Type: Article

References (28)

1. Howden BP, Davies JK, Johnson PD Ret al. Reducedvancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistancemechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
2. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
3. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
4. Chang H-J, Hsu P-C, Yang C-C et al. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillinresistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study. J Antimicrob Chemother 2012; 67: 736-41.
5. Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 2008; 31 Suppl 2: 1-9.
6. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
7. Cui L, Neoh H-M, Shoji M et al. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 1231-4.
8. Neoh H-M, Cui L, Yuzawa H et al. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycinintermediate resistance. Antimicrob Agents Chemother 2008; 52: 45-53.
9. Howden BP, Stinear TP, Allen DL et al. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 3755-62.
10. Shoji M, Cui L, Iizuka R et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 3870-81.
11. Doddangoudar VC, O'Donoghue MM, Chong EYC et al. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2012; 67: 2101-6.
12. Gardete S, Kim C, Hartmann B Met al. Geneticpathwayin acquisitionand loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog 2012; 8:e1002505.
13. Cui L, Isii T, Fukuda M et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 5222-33.
14. Watanabe Y, Cui L, Katayama Y et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 2680-4.
15. Mwangi MM, Wu SW, Zhou Y et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 2007; 104: 9451-6.
16. Katayama Y, Murakami-Kuroda H, Cui Let al. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother 2009; 53: 3190-6.
17. Howe RA, Monk A, Wootton M et al. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004; 10: 855-7.
18. Hafer C, Lin Y, Kornblum J et al. Contributionof selectedgenemutationsto resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 5845-51.
19. Huang Y-C, Chen C-J. Community-associated methicillin-resistant Staphylococcus aureus in children in Taiwan, 2000s. Int J Antimicrob Agents 2011; 38: 2-8.
20. Wang WY, Lee SY, Chiueh TS et al. Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus isolates from patients with septic arthritis. J Clin Microbiol 2009; 47: 3617-23.
21. Traber KE, Lee E, Benson S et al. agr function in clinical Staphylococcus aureus isolates. Microbiology 2008; 154: 2265-74.
22. Rumble SM, Lacroute P, Dalca AV et al. SHRiMP: accurate mapping of short color-space reads. PLoS Comput Biol 2009; 5: e1000386.
23. Wootton M, Howe RA, Hillman Ret al. Amodifiedpopulationanalysisprofile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
24. Patel N, Pai MP, Rodvold KA et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52: 969-74.
25. Besier S, Ludwig A, Brade V et al. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol Microbiol 2003; 47: 463-9.
26. ChenH-J, HungW-C, Tseng S-P et al. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2010; 54: 4985-91.
27. Turnidge J, Collignon P. Resistance to fusidicacid. Int J AntimicrobAgents 1999; 12 Suppl 2: S35-44.
28. Mason BW, Howard AJ. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study. Int J Antimicrob Agents 2004; 23: 300-3.